中国生物工程杂志

[1] Miyata A, Arimura A, Dahl R R, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun, 1989, 164(1): 567-574.
[2] Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept, 1992, 37(3): 285-303.
[3] Pantaloni C, Brabet P, Bilanges B, et al. Alternative splicing in the N-terminal extracellular domain of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor modulates receptor selectivity and relative potencies of PACAP-27 and PACAP-38 in phospholipase C activation. J Biol Chem, 1996,271(36):22146-22151.
[4] Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev, 2009, 61(3):283-357.
[5] Arimura A, Shioda S. Pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors: neuroendocrine and endocrine interactin. Front Neuroendocrinol, 1995, 16(1): 53-88.
[6] Waschek J A,Casillas R A,Nguyen T B, et al. Neural tube expression of pituitary adenylate cyclase activating peptide (PACAP) and receptor: potential role in patterning and neurogenesis. Proc Natl Acad Sci U S A,1998,95(16):9602-9607.
[7] Jamen F,Persson K,Bertrand G, et al. PAC1 receptor deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance. J Clin Invest,2000,105(9):1307-1315.
[8] Garcia-Fernandez M O,Bodega G,Solano R M, et al. Expression and distribution of pituitary adenylate cyclase activating peptide in human prostate and prostate cancer tissues. Regul Pept,2002,110(1):9-15.
[9] Philip B Daniel, Timothy J Kieffer, Colin A Leech, et al. Novel alternatively spliced exon in the extracellular ligand-binding domain of the pituitary adenylate cyclaseactivating polypeptide (PACAP) type 1 receptor (PAC1R) selectively increases ligand affinity and alters signal transduction coupling during spermatogenesis. J Biol Chem, 2001,276(16): 12938-12944.
[10] Yu R J, Yi T Y, Xie S S, et al. Long-term administration of maxadilan improves glucose tolerance and insulin sensitivity in mice. Peptides, 2008,29(8):1347-1353.
[11] Beinborn M.Class B GPCRs: a hidden agonist within? Mol Pharmacol, 2006,70(1): 1-4.
[12] Ushiyama M,Ikeda R, Sugawara H, et al. Differential intracellular signaling through PAC1 isoforms as a result of alternative splicing in the first extracellular domain and the third Intracellular loop. Mol Pharmacol,2007,72(1):103-111.
[13] Yu R J, Yi T H, Zhang L, et al. Intein-mediated rapid purification of recombinant maxadilan and M65 and their acute effects on plasma glucose. Acta Biochim Biophys Sin, 2008,40(12):1015-1022.
[14] Buscail L, Gourlet P, Cauvin A, et al. Presence of highly selective receptors for PACAP (pituitary adenylate cyclase activating peptide) in membranes from the rat pancreatic acinar cell line AR 4-2J. FEBS Lett, 1990,262(1):77-81.
[15] Fukiage C, Nakajima T,Takayama Y, et al. PACAP induces neurite outgrowth in cultured trigeminal ganglion cells and recovery of corneal sensitivity after flap surgery in rabbits. Am J Ophthalmol, 2007,143(2):255-262.
[16] Dautzenberg F M, Mevenkamp G,Wille S, et al. N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants. J Neuroendocrinol,1999,11(12):941-949.
[17] Yu R J, Li J, Wang J J, et al. The functional recombinant first extracellular (EC1) domain of PACAP receptor PAC1 normal form (PAC1-EC1(N)) recognizes selective ligands and stimulates the proliferation of PAC1-CHO cells. Neuroscience Letters, 2010,480 (7):73-77.
[18] Cao YJ,Gimpl G,Fahrenholz F. The amino-terminal fragment of the adenylatecyclase activating polypeptide (PACAP) receptor functions as a high affinity PACAP binding domain. Biochem Biophys Res Commun,1995,212(2):673-680.
[19] Bourgault S, Vaudry D,Ségalas-Milazzo I, et al. Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor. J Med Chem, 2009,52(10): 3308-3316.
[20] Robberecht P,Gourlet P, De Neef P, et al.Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes.Discovery of PACAP(6-38) as a potent antagonist. Eur J Biochem, 1992,207(1):239-246.
[21] 易天红,洪岸,谢珊珊,等.重组Maxadilan的制备与鉴定.生物工程学报,2008,24(12):2049-2055. Yi T H,Hong A,Xie S S, et al. Chinese Journal of Biotechnology, 2008,24(12):2049-2055.
[22] Meyer D K.The effects of PACAP on neural cell proliferation. Regulatory Peptides, 2006,137(1-2):50-57.
[23] Laburthe M, Couvineau A, Tan V. Class Ⅱ G protein-coupled receptors for VIP and PACAP:Structure, models of activation and pharmacology. Peptides,2007,28(9):1631-1639.